A double-blind controlled study of MK-486 in Parkinson's disease.
D000368:Aged; D000856:Anorexia Nervosa / Q000209:etiology; D000978:Antiparkinson Agents / Q000009:adverse effects* / Q000627:therapeutic use*; D002230:Carbidopa / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D002986:Clinical Trials as Topic; D004295:Dihydroxyphenylalanine / Q000008:administration & dosage / Q000627:therapeutic use; D005069:Evaluation Studies as Topic; D005260:Female; D006801:Humans; D006834:Hydrazines / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D009325:Nausea / Q000209:etiology; D010300:Parkinson Disease / Q000188:drug therapy*; D010919:Placebos
D000978:Antiparkinson Agents; D006834:Hydrazines; D010919:Placebos; D004295:Dihydroxyphenylalanine; D002230:Carbidopa